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 ABSTRACT 
Objective: Is the addition of Omega-3 fatty acids to other treatment methods effective in 
reducing pain in adult patients with osteoarthritis? 
Study design: Review of three published, double blind, randomized controlled trials were used 
for this review and were selected based on their relevance to the clinical question. 
Data source:  The most recent randomized control trials examining the relief of osteoarthritic 
pain with intake of omega-3 fatty acids in addition to traditional medical therapies were found 
using Medline, PubMed, and OVID databases. 
Outcome measured: Relief of osteoarthritic pain with the addition of omega-3 fatty acids to the 
patients’ normal therapy was the outcome measured.  Attention was also paid to the occurrence 
of reported adverse events in all three studies. 
Results: Gruenwald et al. demonstrated that the addition of omega-3 fatty acids to glucosamine 
sulfate was significantly superior to the use of glucosamine sulfate alone in reducing pain by 90-
100% (n= 26 vs 12, respectively; Pchi= 0.014).  Jacquet et al. demonstrated that the addition of 
omega-3 fatty acids, in the form of Phytalgic, to regular NSAID and analgesic use significantly 
reduced osteoarthritic pain (86.5) when compared to regular NSAID and analgesic use alone 
(235.3) assessed by WOMAC pain scores after three months of therapy with a p-value <0.001. 
Stammers et al. discovered no significant pain relief in patients taking 786mg eicosapentaenoic 
acid, in the form of cod liver oil, in addition to regular NSAIDs compared to patients taking a 
placebo (olive oil) in addition to regular NSAIDs after assessment with a t-test.   
Conclusions: Although inconclusive, the results of these three randomized controlled trials 
demonstrates that the addition of omega-3 fatty acids to regular treatment modalities for 
relieving osteoarthritic pain is effective and deserves further investigation. 
Key words: osteoarthritis, omega-3 fatty acids, fish oil 
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INTRODUCTION 
Osteoarthritis (OA), a degenerative joint disease, is managed with a wide range of 
treatment strategies from acetaminophen to joint replacements.  Omega-3 fatty acids are not 
encouraged as an approved treatment for OA despite the growing evidence of the herbal 
supplement’s ability to decrease inflammation in disease states such as hyperlipidemia, 
rheumatoid and juvenile arthritis.1 This paper will examine the results of three double blind, 
randomized clinical trials that explore the efficacy of using omega-3 fatty acids to relieve 
osteoarthritic pain.   
OA is the most common chronic musculoskeletal disease with higher frequency in obese 
individuals, females, and those aged over 60 years.  There are an estimated 21.4 million older 
Americans living with OA in 2005 which is expected to increase to 41.1 million by 2030.2  OA 
affects 13.9% of adults older than 25 years and 33.6% of adults older than 65 years (12.4 million 
people over 65 years).3 Prevalence is predicted to rise by 66-100% by 2020 due to the increase in 
age and obesity.4 
Annual cost is estimated at 7.9 billion dollars due to knee or hip OA replacement 
surgeries in 20095 which translates to approximately $36.5K per person during a 90 day period 
around a total joint replacement surgery6. Total annual out of pocket expenses have been 
estimated to cost Americans $3,000 with total costs estimated at $5,700 annually.7 OA was the 
primary diagnosis for 735,087 hospitalizations (1.9% of all discharges) in 20068 and 7.1 million 
ambulatory visits (0.7%) in 19979.   
OA is an extensively studied disease due to its widespread prevalence and disability. OA 
is a joint degenerative disease marked by cartilage loss and osteophyte formation due to a 
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cytokine-driven inflammatory response which commonly affects the knees, cervical and lumbar 
spine, hips, and first metatarsal phalangeal joint.  While much is known about the mechanism of 
disease, clinical features and risk factors, researchers have not found a cure nor has a widely 
successful non-invasive therapy been accepted to definitively treat OA. As previously 
mentioned, therapeutic management for OA ranges widely.  Non-pharmacologic therapy 
includes patient education, physical therapy, occupational therapy, correction of malalignment, 
and unloading the joint through weight loss, bracing, shoe inserts, or activity modification.  The 
gold standard pharmacologic therapy is acetaminophen 1.6-4g/d PO, although topical and oral 
non-steroidal anti-inflammatory drugs are also used.  Narcotics (tramadol, opioids), serotonin 
and norepinephrine reuptake inhibitors (duloxetine) have been found to be beneficial and 
approved in treating osteoarthritic pain in conditional cases.10, 11 Corticosteroid (triamcinolone) 
or Na+ hyaluronic acid injections have been found to be effective in managing osteoarthritic 
pain.  Some cases require surgery which includes osteotomy to fix malalignment, or partial/total 
joint replacement surgeries.  Surgical joint replacements act as the most definitive therapy to 
treat OA to date.  Prevention therapies include weight loss, correct leg length discrepancy, 
vitamin D supplements, chondroitin sulfate, glucosamine, hyaluronic acid.  Omega-3 fatty acids 
have been shown to decrease inflammatory markers (IL-6 and TNFα) in juvenile arthritis1 and 
inhibit inflammatory mediators (eicosanoids and cytokines) to aid in the treatment of rheumatoid 
arthritis and cardiovascular disease12. Because cytokines and other inflammatory biomarkers 
contribute to the osteophyte formation in OA disease pathogenesis, it can be assumed that the 
anti-inflammatory abilities of omega-3 fatty acids may aid in the treatment of OA.  The objective 
of this selective EBM review is to determine whether or not the addition of omega-3 fatty acids 
to other treatment methods is effective in reducing pain in adult patients with OA. 
Martin, Addition of Omega-3 Fatty Acids in Osteoarthritic Pain Reduction, 3 
METHODS 
This review focused on adults with OA. The intervention studied was the addition of 
omega-3-fatty acids to current medical therapy. Gruenwald et al. studied pain relief with 
glucosamine sulfate 500mg alone against an experimental group taking glucosamine sulfate 
500mg with omega-3-fatty acids.13  Jacquet et al. compared pain relief with usual 
NSAID/analgesic use with a placebo to an experimental group taking usual NSAID/analgesic in 
addition to Phytagic, a supplement containing omega-3 FA.14  Stammers et al. compared pain 
relief with usual NSAID use with 10ml olive oil to an experimental group taking NSAIDs in 
addition to cod liver oil which contains EPA, an ingredient of omega-3 FA.15  Though many 
outcomes were measured in each study, the one outcome of concern was pain relief. The three 
studies were double blind randomized control clinical trials (RCT). Inclusion criteria included 
recent RCTs examining the effects of treating osteoarthritic pain with omega-3 fatty acids in 
addition to other medications in adults with OA. Exclusion criteria included patients younger 
than 25 years.  Databases accessed to search articles included Medline, PubMed, and OVID and 
keywords included osteoarthritis, omega-3 fatty acids and fish oil.  Each article was published in 
peer-reviewed journals and written in English. Statistical data analysis included the U-test, 
Mann-Whitney U-test, Chi-squared test, and repeated measures with confidence intervals (CI) 
set at 95% and p-value significance set at 5% in the study by Gruenwald et al.; t-tests, U-tests, 
Chi-squared, and Fischer tests with a CI set at 95% and p-value significance set at 5% in the 
study by Jacquet et al.; t-test and Mann-Whitney U-test in the study by Stammers et al. 
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Table 1: Demographics and characteristics of included studies 
Article Type of 
Study 
# 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Intervention 
2009 
Gruenwal
d J, 
Petzold 
E, Busch 
R, 
Petzold 
HP, 
Graubau
m HJ 
2-center, 2-
armed, 
randomized, 
double blind, 
comparison 
study 
177 
knee
/hip 
OA 
 
62.3  40-75yo, 
untreated 
OA sx, mod-
severe hip or 
knee OA 
(WOMAC 
pain score= 
300-400), 
limited 
function of 
hip or knee 
Systemic dz, 
kidney/liver/GI dz; 
steroidal or non-
steroidal anti-
rheumatic, 
analgesics; allergy 
to ingredients; 
gamma-linolenic 
acid, glucosamine 
+/- chondroitin, 
alcohol, meds, 
drugs; HIV, AIDS, 
pregnant 
1 
 
1.5g 
glucosamine 
sulfate  
vs. 
 
1.5g 
glucosamine 
sulfate + 
600mg 
omega-3 FA 
x 26wks 
2009 
Jacquet 
A, 
Girodet 
PO, 
Pariente 
A, Forest 
K, Mallet 
L, Moore 
N 
Randomized, 
double blind, 
parallel-arms 
clinical trial 
81 
knee
/hip 
OA 
57.1 40-80yo, 
chronic 
knee/hip OA 
evidenced 
by hx & X-
ray 
evidence, 
taking 
NSAIDS 
&/or 
analgesics 
 
 
Pregnant or 
lactating, shorter 
life expectancy than 
trial duration, 
inflammatory 
arthritis, OA not 
affecting knees or 
hips, allergy to 
product ingredients 
5 
 
Placebo + 
usual 
NSAID/anal
gesics  
vs.  
 
Phytalgic 
(fish oil, 
vitamin E, 
Urtica 
dioica)- in 
addition to 
pts usual 
NSAID/anal
gesics 
x 12wks 
1992 
Stammer
s T, 
Sibbald 
B, 
Freeling 
P 
Double 
blind, 
placebo 
controlled 
randomized 
clinical trial 
86 
OA 
pts 
 
68 49-87yo, 
pain 
associated 
with OA 
even while 
taking 
NSAIDS 
2wks prior 
to start of 
trial 
N/A 22 
 
10ml olive 
oil + 
NSAIDs  
vs.  
 
10ml cod 
liver oil 
(756mg 
EPA) + 
NSAIDs 
x 24wks 
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OUTCOMES MEASURED 
Perception of pain caused by OA was measured by a standardized pain scale called the 
Western Ontario and McMaster Universities Arthrosis (WOMAC) in the first two studies13, 14 
and by a visual analog scale (VAS) from 1-10 in the third study15.  Gruenwald et al. also studied 
pain relief determined via VAS.13  Other outcomes measured were efficacy and safety perceived 
by the patient and practitioner, unwanted effects or harm perceived by the patient and assessed 
by the practitioner, activity limitations and disability perceived by the patient, and joint pain & 
inflammation assessed by the doctor. The latter outcomes were not evaluated in this study. 
RESULTS 
Efficacy of Results 
All three RCTs explored the effect of adding omega-3 fatty acids to regular use of other 
treatment modalities in relieving osteoarthritic pain. The studies differed in measurement of pain, 
omega-3 fatty acid product used and comparison therapy. Gruenwald et al. examined the effects 
of adding 600 mg omega-3 fatty acids to 1.5 g glucosamine sulfate against 1.5 g glucosamine 
sulfate with an oil mixture containing all the same ingredients except EPA and DHA in reducing 
hip and knee osteoarthritic pain over 26 weeks in 177 patients.13 This study used the Western 
Ontario and McMaster Universities Arthrosis (WOMAC) scale to assess pain relief as well as a 
VAS measuring the patient’s perception of pain intensity. The main results from this study 
showed that the addition of omega-3 fatty acids to glucosamine sulfate was significantly superior 
in pain relief when compared to using glucosamine sulfate with a placebo oil.  While no 
significant difference was observed between the control and experimental group in reducing pain 
by less than 80%, significantly more patients who took omega-3 fatty acids with glucosamine 
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sulfate, experienced more than 90% pain reduction (n= 26) when compared to those who took 
glucosamine sulfate with placebo (n= 12) (Pchi= 0.014).  Pain reduction measured via VAS from 
baseline to the end of the study showed that the experimental group experienced more pain 
reduction than the control group, although these results were not significant.  The second study 
by Jacquet et al. examined the effects of omega-3 fatty acids in the form of Phytalgic, a medical 
food, against a placebo each with the addition of regular use of NSAIDs.14 This study used the 
WOMAC scale to assess hip and knee osteoarthritic pain relief in 86 subjects.  The main results 
from this study showed significant OA pain reduction after taking omega-3 fatty acids in 
combination with regular NSAID and analgesic use (86.5) when compared to regular NSAID 
and analgesic use alone (235.3) assessed by WOMAC pain scores after three months of therapy 
(p-value <0.001). The third study by Stammers et al. examined the effects of adding 756 mg 
EPA, a component of omega-3 fatty acid, in cod liver oil against a placebo, olive oil, to the 
patients’ regular use of NSAIDs.15 This study used a VAS to assess OA pain relief at 6 intervals 
during a 24 week period in 86 patients. This study demonstrated no significant pain relief in 
patients taking 786 mg eicosapentaenoic acid, in the form of cod liver oil, in addition to regular 
NSAIDs compared to patients taking a placebo (olive oil) in addition to regular NSAIDs after 
assessment with a t-test.   
Treatment effects 
In the study by Gruenwald et al., four patients in the control group experienced more than 
90% pain reduction from baseline whereas 13 patients in the experimental group experienced 
more than 90% pain reduction from baseline.  This equates to a control event rate (CER) of 5% 
and an experimental event rate (EER) of 14%, which yields a relative benefit increase (RBI) of 
1.8 or 180% and an absolute benefit increase (ABI) of 0.09.  Using RBI, the numbers needed to 
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treat (NNT) was calculated to be 11.1, meaning a health care provider needs to treat 12 adult 
patients with hip or knee osteoarthritic pain with adding omega-3 fatty acids to 500 mg 
glucosamine sulfate to have one additional patient experience more than 90% pain reduction.  
Twenty one patients experienced adverse effects, 12 from the experimental group and nine from 
the control group showing no significant difference.  This yields a CER of 10% and an EER of 
13%.  The reported adverse events varied from mild to strong but none were considered serious.  
The relative risk increase (RRI) was calculated to be 0.291 or 29% and the absolute risk increase 
(ARI) was 0.03 or 3%.  Numbers needed to harm (NNH) was calculated to be 33 from the 
equation 1/ARI, meaning for every 33 patients treated with the addition of omega-3 fatty acids to 
glucosamine sulfate, one patient would experience an adverse event. Two subsets of each group 
was reported on.  The full case analysis set (FAS) included 177 patients and the valid case 
analysis set (VCAS) included 164 subjects who met the full inclusion and compliance standards 
throughout the study.  Both the FAS and VCAS groups were significant in pain reduction by 
more than 90% in the experimental group compared to the control in this study.  
In the second and third study, there was no dichotomous data in which to report NNT so 
only NNH was calculated.  In the study by Jacquet et al., 13 of the 40 patients in the control 
group and 14 out of the 41 patients in the experimental group experienced adverse effects, giving 
a CER of 32% and an EER of 34%.14 Although adverse events ranged from pain to infection, to 
pregnancy, only digestive adverse events were attributed to the experimental drug (flatulence, 
diarrhea, fish smelling eructations).  The RRI was calculated to be 0.063 or 6% and the ARI was 
calculated to be 0.02 or 2%.  The NNH was found to be 50, meaning for every 50 patients treated 
with omega-3 fatty acids in the form of Phytalgic in addition to NSAIDs and analgesics, one 
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patient would experience an adverse event.  Two patients were withdrawn from the study, one 
from each group which did not alter the results.  
In the study by Stammers et al., 23 total patients reported adverse effects of treatment, 10 
in the control group (24%) and 13 (30%) in the experimental group.15  The adverse events varied 
from gastrointestinal complaints to dry skin, although no discernible relationship was found.  
RRI was calculated to be 25% and the ARI was 6%.  NNH was found to be 17, meaning for 
every 17 patients treated with omega-3 fatty acids, in the form of cod liver oil, in the addition to 
regular NSAID and analgesic use, one patient would experience an adverse event.  Twenty two 
patients failed to complete the study, 13 in the experimental group and nine in the control group 
without a comment in the article on how this drop-out rate influenced the results. 
Table 2: Treatment effects 
Study RBI ABI NNT RRI ARI NNH 
Gruenwald et al 180% 0.09 12 29% 3% 33 
Jacquet et al N/A N/A N/A 6% 2% 50 
Stammers et al N/A N/A N/A 25% 6% 17 
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DISCUSSION 
This systematic review demonstrates a possible aid in osteoarthritic pain relief by adding 
omega-3 fatty acids to other treatment modalities. Two of the three studies revealed pain relief 
after the addition of omega-3 fatty acids, however many questions remain unanswered and 
limitations of each study must be discussed. Due to the wide variation in both the control and 
experimental group therapies used in the current articles, it is difficult to estimate the exact role 
and efficacy of omega-3 fatty acids in treatment of osteoarthritic pain. Gruenwald et al. looked at 
the addition of 600 mg omega-3 fatty acids to 1.5 g glucosamine sulfate in comparison to 1.5 g 
glucosamine sulfate and placebo oil mixture.13  Both oils contained vitamin A, D and E with the 
presence of eicosapentaenoic acid (EPA) and doxosahexaenoic acid (DHA) being the only 
difference in the oils. The amount of omega-3 oil as well as glucosamine sulfate was set at the 
above amount with compliance met if the patients took between 75% and 125% of this specified 
amount.  The second study used Phytalgic in the intervention group which is a medical food 
consisting of omega-3 fatty acids, omega-6 fatty acids, Urtica dioica (a common nettle), zinc and 
vitamin E against a placebo which contained all the same except for a lack of omega-3 fatty 
acids and omega-6 fatty acids.14 Studying the effects of the omega-3 component alone is 
impossible as Urtica dioica has been found to have an analgesic effect, zinc has been found to 
decrease inflammation.  Also in the exclusion of both omega-3 fatty acids and omega-6 fatty 
acids from the placebo, it becomes difficult to determine which component is the one that can be 
associated with the outcome of the study.  Also of importance, the amount of omega-3 fatty acids 
was not specified (the article only specified the patients took 3 capsules) and the amount of 
analgesics and NSAIDs are varied because part of the objective of the study was to examine if 
there was a decrease in the regular voluntary use of analgesics or NSAIDs when taking 
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Phytalgic. Furthermore, omega-6 fatty acids have been associated with initiating inflammation.16 
The third study differs in that it uses 10 ml cod liver oil which contains 756 mg EPA in 
comparison to a placebo of 10 ml olive oil.  Olive oil contains over 30 polyphenols, some of 
which have anti-inflammatory properties17 and have been found to aid in pain treatment of 
rheumatoid arthritis suggesting it may be beneficial in treating OA pain.  Use of other 
medications varied widely between opioids, NSAIDs and analgesics although the researchers set 
a specified dose of each drug. 
While all three studies were double blinded to avoid bias, it may be assumed that it is 
well understood that “fishy burps” are a common side effect of omega-3 fatty acids (fish oil) 
supplements and therefore, patients taking experimental omega-3 fatty acid products with “fishy 
burps” may have biased response to pain if they are predisposed to their treatment modality.  The 
study by Jacquet et al. took this fact into consideration when they found no change in their 
results when they excluded the two patients that complained of fishy burps.14 
All studies were funded by groups with competing interests.  The study by Gruenwald et 
al. and the study by Stammers et al. were funded by Seven Seas Limited, Hull UK.  The study by 
Jacquet et al. was funded by Laboratoires Phythea.  
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CONCLUSION 
Although further studies are warranted, after reviewing these three studies, the addition of 
Omega-3 fatty acids to other therapy is efficacious in the treatment of osteoarthritic joint pain.  
In all three studies a greater sample size with more control of “other treatment modalities” and a 
more targeted population would be beneficial to answering more targeted questions regarding the 
efficacy of omega-3 fatty acids on treating osteoarthritic pain.  More targeted questions could 
aim at the effect of omega-3 fatty acids on osteoarthritic pain in specific joints or in males as 
compared to females or in combination with specified “other medications”.  As outlined above, 
the treatment modalities of the studies differed greatly affecting the ease at which the studies and 
their results could be compared.  Future studies should concentrate on standardizing the amount 
of DHA and EPA while eliminating the other substances that could potentially influence the 
inflammation disease process of OA which will help identify the role of omega-3 fatty acid in 
relieving OA pain.  Standardizing the control group to a defined type and amount of “other 
treatment modality” would also help confine the results to reflecting the influence of the addition 
of omega-3 fatty acids.  Because of the many joints affected in OA, it may be useful to separate 
the joints in future studies because of the weight bearing effects on inflammation.  Future 
research should focus on the treatment of omega-3 fatty acids in relieving osteoarthritic pain in 
weight bearing joints such as the lower extremity (knees and hips) or lumbar spine as opposed to 
the non-weight bearing joints of the upper extremities as the weight bearing joints may exhibit 
more inflammation. 
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